HIGHLIGHTS FROM PROBIOTA 2017 IN BERLIN

Is pharma interest in probiotics a challenge or opportunity?

Loading the player...

The probiotic category continues to grow rapidly on a global basis. And with growth comes increased interest probiotics and microbiome modulation therapies from the pharmaceutical sector. But is this increased interest a good thing for the traditional probiotic players?

The recent Probiota event in Berlin brought together leading experts in research and business to discuss the state of play in probiotics, prebiotics and microbiome modification.

NutraIngredients asked for expert insights on a range of topics. Here we asked experts from the business and research world whether increased interest in the microbiome and probiotics from big pharmaceutical is a challenge or opportunity for long-established probiotics researchers and suppliers.

Susanne Baekgaard of Bifodan told us that the use of drug development technologies and methodologies for the development of probiotic strains and science 'can be beneficial', while Amy Smith of DuPont said the probiotic industry working with the pharmaceutical industry is 'very promising' and "could really make a difference in people's lives."

"Probiotics, as they are today, are generally used as dietary supplements where they can be manufactured according to dietary supplement GMPs, and crossing the line over to the world of pharmaceuticals would mean a difference in manufacturing where pharmaceutical GMPs would have to be followed and there would be a change in the manufacturing process," said Smith.

Related News

Biofilms of the sort that the BIOHM product is meant to address.  PathoBiome photo.

New probiotic meant to balance microbial, fungal communities in gut

Strain-level specificity critical for full compliance, NSF probiotics labeling expert says

Strain-level specificity critical for full compliance, NSF probiotics labeling expert says

Science builds for probiotics' effects on depression symptoms

Lallemand furthers study on probiotic intervention among individuals newly diagnosed with depression

Craftier study designs could outline environmental view of microbiome

Outlining 'environmental' view of microbiome awaits craftier study designs, experts say

DuPont invests $10 million to upgrade Wisconsin probiotic facility

DuPont invests $10 million to upgrade Wisconsin probiotic facility

Lallemand to highlight its ProbioKid line at SupplySide West

Probiotic maker Lallemand highlights strains, formulations for children and teenagers

The Vitamin Shoppe expands ProBioCare line with DUOCAP products

The Vitamin Shoppe expands probiotic ProBioCare line, adds products with DUOCAP technology

Related Products

See more related products